Aurigene.AI: The End-to-End AI Platform Redefining Drug Discovery from Target to Candidate

Overview: How Aurigene.AI’s AI-Driven End-to-End Drug Discovery Platform Transforms Pharma R&D

Aurigene.AI is an AI- and ML-assisted end-to-end drug discovery platform that supports target discovery, generative chemistry, and candidate prioritisation within early-stage R&D. It is designed to address the bottleneck of slow, data-intensive design–make–test–analyse cycles by combining curated datasets, predictive models, and physics-based simulation to improve how teams select and refine molecules.

At a high level, the platform uses generative and predictive algorithms alongside CADD and experimental feedback to rank compounds, assess properties such as potency and ADME, and guide more efficient hit-to-lead progression. For research teams, this can reduce iteration time, support faster go/no-go decisions, and improve the quality of candidate selection before costly lab work expands.

Last checked on July 28, 2026: Aurigene.AI remains active within Aurigene Pharmaceutical Services, with recent updates emphasising AI-driven DMTA workflows, predictive modelling, and large-scale virtual screening.

What is Aurigene.AI?

Aurigene.AI is an AI-assisted drug discovery platform within Aurigene Pharmaceutical Services’ broader CRDMO offering, used for hit identification, candidate prioritisation, and early-stage molecular design. It appears aimed at pharmaceutical and biotech R&D teams rather than clinicians or hospitals, and combines AI/ML with CADD, physics-based simulation, and lab-in-the-loop workflows to support small-molecule discovery across the DMTA cycle.

Public sources describe the platform as supporting target discovery through preclinical candidate selection, with data-driven screening and ADMET-oriented prediction integrated into the workflow. Aurigene also frames the offering as part of an established global drug-development organisation, which may matter for buyers evaluating delivery capacity and scientific support.

Why Do Leading Healthcare Teams Trust Aurigene.AI?

• Aurigene.AI is embedded in Aurigene Pharmaceutical Services, a broader CRDMO with 25+ years of operating history and a large global delivery footprint.aurigeneservices+2

• The company sits within Dr. Reddy’s Laboratories’ ecosystem, which adds corporate backing and operational stability.

• Aurigene.AI has an announced partnership with Vipergen to co-market and offer DNA-encoded library screening services.

• Aurigene Pharmaceutical Services has also reported a research collaboration with Alveus Therapeutics, with Aurigene providing AI-enabled discovery support.

• The broader organisation has public collaboration history with EQRx in drug discovery, preclinical development, and commercialisation.

• Aurigene and Edity Therapeutics announced a strategic cell-therapy partnership, indicating active life-science collaboration beyond software-only use.

• The Aurigene.AI team received the Dr. Anji Reddy Award for Excellence for enterprise excellence breakthrough impact in 2026.

• Aurigene Pharmaceutical Services publicly received an ET Pharma award for excellence in digital transformation tied to Aurigene.AI implementation.

• Public posts also cite recognition for a generative-AI-based platform and an innovative GenAI application award in 2025.